Shionogi & Co., Ltd.
【Shionogi & Co., Ltd.】2026 Fiscal Year Earnings｜Sales of ¥499.7 billion (Up 14.0% YoY)
Shionogi & Co., Ltd. achieved sales of ¥499.7 billion (14.0% increase) for the fiscal year ending March 2026, with operating profit of ¥166.7 billion (6.5% increase) and net income attributable to owners of the parent of ¥205.9 billion (20.4% increase), setting new records. The company is strengthening sales and R&D investments domestically and internationally, expecting continued high growth this period.
Key Figures
- Sales Revenue: ¥499.7 billion (up 14.0% YoY)
- Net Income Attributable to Owners of Parent: ¥205.9 billion (up 20.4%)
- Total Assets: ¥2.5768 trillion
AI要約
Summary of Business Performance
Shionogi & Co., Ltd. recorded a new high for the fiscal year ending March 2026 with sales of ¥499.7 billion (up 14.0% YoY) and operating income of ¥166.7 billion (up 6.5%). The expansion of pharmaceutical sales domestically and internationally, along with M&A-driven business expansion, has actively advanced R&D investments. Particularly, new drugs in infectious disease and QOL disorder areas have progressed through development and approval, projecting continued high growth in the next period. Overseas sales continues steadily, strengthening the revenue foundation through royalty income and new drug launches.
Future Outlook and Impact on Shareholders
The consolidated earnings forecast for the fiscal year ending March 2027 projects sales of ¥700.0 billion (up 40.1%) and net income of ¥21.0 billion (up 2.4%). Stable income from infectious disease drugs and accelerated new drug development are expected to sustain high growth. Plans include stock splits and increased dividends, aiming to balance shareholder returns with business expansion. By advancing research investments and global development, the company aims for sustainable growth.
Shionogi & Co., Ltd.
Company overview · Stock price · Financial data · All IR
